Stock Fundamentals

Company Information

Company Name
Protagonist Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US74366E1029
CIK: 0001377121
CUSIP: 74366E102
Currency: USD
Full Time Employees: 131
Phone: 510 474 0170
Fiscal Year End: December
IPO Date: Aug 11, 2016
Description:

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Address:

7707 Gateway Boulevard, Newark, CA, United States, 94560

Directors & Officers

Name Title Year Born
Dr. Dinesh V. Patel Ph.D. CEO, President, Secretary & Director 1957
Mr. Asif Ali Executive VP & CFO 1974
Dr. Arturo M. Molina FACP, M.D., M.S. Chief Medical Officer 1959
Mr. Venkat Thalladi Ph.D. EVP & Chief Technical Officer NA
Dr. Newman Yeilding M.D. Executive VP, Chief Scientific Officer NA
Mr. Matthew M. Gosling J.D. Executive VP and Chief Legal & Business Officer 1971
Ms. Carena Spivey Executive VP & Chief Human Resources Officer NA
Dr. Ashok Bhandari Ph.D. EVP & Chief Discovery Officer 1964
Mr. Carter J. King Executive Vice President of Business Development 1971
Ms. Abha Bommireddi Executive VP & Chief of Staff NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 20, 2026 Asif Ali N/A Sale 1.75K $105.47 $184.57K
Mar 26, 2026 Arturo Md Molina N/A Sale 15.00K $104.79 $1.57M
Mar 26, 2026 Asif Ali N/A Sale 24.77K $104.24 $2.58M
Mar 26, 2026 Harold E Selick N/A Sale 24.00K $105.00 $2.52M
Mar 25, 2026 Dinesh V Ph D Patel N/A Sale 54.64K $101.00 $5.52M
Mar 24, 2026 Dinesh V Ph D Patel N/A Sale 59.00 $101.00 $5.96K
Feb 17, 2026 Lewis T Williams N/A Sale 18.00K $82.42 $1.48M
Feb 06, 2026 William D Waddill N/A Sale 20.00K $83.68 $1.67M
Jan 27, 2026 Arturo Md Molina N/A Sale 5.00K $82.00 $410.00K
Jan 27, 2026 Asif Ali N/A Sale 46.20K $83.13 $3.84M
Jan 27, 2026 Dinesh V Ph D Patel N/A Sale 4.07K $83.19 $338.42K
Jan 26, 2026 Dinesh V Ph D Patel N/A Sale 24.89K $84.03 $2.09M
Jan 23, 2026 Arturo Md Molina N/A Sale 13.15K $82.42 $1.08M
Jan 23, 2026 Dinesh V Ph D Patel N/A Sale 19.32K $84.59 $1.63M
Jan 20, 2026 Arturo Md Molina N/A Sale 9.51K $82.48 $784.71K
Jan 20, 2026 Asif Ali N/A Sale 8.59K $82.48 $708.34K
Jan 20, 2026 Dinesh V Ph D Patel N/A Sale 34.44K $82.48 $2.84M
Oct 10, 2025 William D Waddill N/A Sale 12.00K $81.62 $979.44K
Sep 22, 2025 William D Waddill N/A Sale 4.00K $64.25 $257.00K
Aug 27, 2025 William D Waddill N/A Sale 4.00K $59.25 $237.00K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 9.78M Mar 31, 2026 15.21% $0.02 0.65%
Farallon Capital Management, L.L.C. 6.35M Mar 31, 2026 9.87% $3.81 3.34%
Vanguard Group Inc 5.41M Dec 31, 2025 8.42% $0.01 27.16%
UBS Group AG 5.18M Mar 31, 2026 8.05% $0.08 86.92%
RTW INVESTMENTS, LLC 5.06M Mar 31, 2026 7.87% $5.31 0.00%
Wellington Management Company LLP 3.60M Mar 31, 2026 5.60% $0.07 13.50%
Vanguard Portfolio Management, LLC 3.48M Mar 31, 2026 5.41% $0.02 0.00%
State Street Corp 3.12M Mar 31, 2026 4.85% $0.01 -2.59%
HHG PLC 2.89M Mar 31, 2026 4.50% $0.15 9.12%
Vanguard Capital Management, LLC 2.81M Mar 31, 2026 4.36% $0.01 0.00%
Johnson & Johnson 2.45M Mar 31, 2026 3.81% $39.57 0.00%
Amvescap Plc. 2.16M Mar 31, 2026 3.37% $0.03 38.07%
Geode Capital Management, LLC 1.67M Mar 31, 2026 2.60% $0.01 14.90%
T. Rowe Price Associates, Inc. 1.67M Mar 31, 2026 2.59% $0.02 18.90%
Citadel Advisors Llc 1.55M Mar 31, 2026 2.41% $0.03 37.74%
Woodline Partners LP 1.41M Mar 31, 2026 2.20% $0.56 0.38%
Bank of America Corp 1.30M Mar 31, 2026 2.01% $0.01 49.32%
Perceptive Advisors LLC 1.23M Mar 31, 2026 1.91% $2.54 -8.85%
Jennison Associates LLC 1.07M Mar 31, 2026 1.67% $0.08 223.71%
Morgan Stanley - Brokerage Accounts 1.02M Mar 31, 2026 1.58% $0.01 15.84%

Shares Statistics

Shares Outstanding: 64.31M
Shares Float: 52.49M
% Insiders: 71.40%
% Institutions: 12,526.80%
Short % Float: 13.40%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 3.57M 5.54% ▲ 0.03% May 29, 2026
2 Vanguard Total Stock Mkt Idx Inv 2.04M 3.18% ▲ 0.29% Apr 30, 2026
3 Vanguard Health Care Inv 1.56M 2.42% ▲ 46.58% Mar 31, 2026
4 Vanguard Small Cap Index 1.47M 2.29% ▼ 0.20% Apr 30, 2026
5 iShares Russell 2000 ETF 1.39M 2.17% ▲ 0.93% May 29, 2026
6 State Street® SPDR® S&P® Biotech ETF 972.10K 1.51% ▼ 0.61% May 31, 2026
7 T. Rowe Price Health Sciences 944.46K 1.47% ▼ 18.74% Apr 30, 2026
8 Vanguard Small Cap Growth Index Inv 824.26K 1.28% ▼ 0.07% Apr 30, 2026
9 Invesco Discovery A 810.09K 1.26% ▲ 15.13% Apr 30, 2026
10 Invesco OFI Small Cap Growth 703.62K 1.09% ▲ 57.05% Mar 31, 2026

Valuation Metrics

Enterprise Value: $6.53B
Trailing P/E: 0.00
Forward P/E: 23.26

Financial Highlights

Market Cap: $7.06B
EBITDA: $-141.02M
PEG Ratio: $0.00
Book Value: $10.21
Earnings/Share: $-1.81
Profit Margin: -154.88%
Operating Margin: -6.47%
ROA (TTM): -12.37%
ROE (TTM): -17.06%
Revenue (TTM): $74.06M
Revenue/Share (TTM): $1.16
Earnings Growth (YOY): 351.30%
Revenue Growth (YOY): 99.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 12.71x 0.00x 0.08x N/A -0.02x
2024-12-31 12.48x 0.00x 0.09x N/A 0.00x
2023-12-31 16.71x 0.00x 0.06x N/A -0.02x
2022-12-31 7.80x 0.01x 0.13x -38.99x -0.02x
2021-12-31 7.74x 0.01x 0.14x -50.72x -0.02x
2020-12-31 7.84x 0.01x 0.14x -107.89x -0.02x
2019-12-31 4.10x 0.14x 0.48x -476.46x -0.14x
2018-12-31 5.26x -0.01x 0.19x N/A -0.03x
2017-12-31 3.55x 0.00x 0.26x N/A 0.00x
2016-12-31 12.94x 0.00x 0.07x N/A 0.00x
2015-12-31 4.54x 0.22x 0.35x N/A -0.15x
2014-12-31 7.34x 0.00x 0.23x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PTGX.US!